Emergent BioSolutions Reports Turnaround Progress at Annual Meeting; All Proposals Approved
At Emergent BioSolutions' 2026 annual meeting, the company reported significant progress in its multi-year turnaround plan for 2025. Key financial highlights include $205 million adjusted EBITDA and a $100 million cash increase. All shareholder proposals were approved.
Tickers: $EBS
Topics: annual meeting executive compensation stock incentive plan turnaround progress